SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-036174
Filing Date
2024-08-08
Accepted
2024-08-08 16:24:38
Documents
52
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20240630.htm   iXBRL 10-Q 1235689
2 EX-31.1 ex-311x20240630.htm EX-31.1 9696
3 EX-31.2 ex-312x20240630.htm EX-31.2 9683
4 EX-32.1 ex-321x20240630.htm EX-32.1 9547
  Complete submission text file 0001628280-24-036174.txt   5391427

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20240630.xsd EX-101.SCH 29915
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20240630_cal.xml EX-101.CAL 56530
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20240630_def.xml EX-101.DEF 192948
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20240630_lab.xml EX-101.LAB 523260
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20240630_pre.xml EX-101.PRE 340967
54 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20240630_htm.xml XML 559588
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 241188809
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)